Faisal Ghiath Sukhtian

CIK: 0001716033

Transaction Breakdown

Open Market Buys (P)2 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OTLK

Outlook Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

OTLK
Outlook Therapeutics, Inc.
Jul 29, 2026
Purchase(P)
Direct
95.4K shares at avg. $1.05$100K
OTLK
Outlook Therapeutics, Inc.
May 27, 2026
Purchase(P)
Direct
122.2K shares at avg. $0.41$50K
OTLK
Outlook Therapeutics, Inc.
Oct 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
117.3K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
286.7K shares-
OTLK
Outlook Therapeutics, Inc.
Feb 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
12.3K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 3, 2024
Award(A)
Stock Option (Right to Buy)
Direct
19.8K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
134.4K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
56.6K shares-

		Type	Shares	Price		Ownership
Jul 29, 2026	OTLK Outlook Therapeutics, Inc.	Purchase(P)	95,398	$1.05	$99,996	Direct
May 27, 2026	OTLK Outlook Therapeutics, Inc.	Purchase(P)	122,174	$0.41	$50,006	Direct
Oct 3, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	117,296	-	-	Direct
Oct 1, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	286,734	-	-	Direct
Feb 4, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	12,323	-	-	Direct
Oct 3, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,771	-	-	Direct
Oct 1, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	134,430	-	-	Direct
Oct 1, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	56,636	-	-	Direct

1-8 of 8 transactions

About Sukhtian Faisal Ghiath

Sukhtian Faisal Ghiath (SEC CIK 0001716033) files insider reports with the SEC as Director of Outlook Therapeutics, Inc. (OTLK).

Signal8 holds 5 ownership filings by Sukhtian Faisal Ghiath, all Form 4s, filed between Oct 3, 2024 and Jul 29, 2026. Those filings report 8 transactions, from Oct 1, 2024 to Jul 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sukhtian Faisal Ghiath's filings is in ISELIN, NJ.

Recent filings by Sukhtian Faisal Ghiath

Jul 29, 2026: Open-market purchase of OTLK shares (Form 4, code P).
May 27, 2026: Open-market purchase of OTLK shares (Form 4, code P).
Oct 3, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
Oct 1, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
Feb 4, 2025: Grant or award of OTLK derivative securities (Form 4, code A).

Other insiders filing for Outlook Therapeutics, Inc. (OTLK)

Lundquist Kevin Michael, Chief Financial Officer
Jahr Robert Charles, Chief Executive Officer
Sukhtian Ghiath M., Director
KENYON LAWRENCE A, Chief Financial Officer
Haddadin Yezan Munther, Director
THURMAN RANDY H, Director

How to read Form 4 transaction codes